
Cleveland Clinic Taussig Cancer Institute
Taussig Cancer Institute is the hub for Cleveland Clinic Cancer Center.
- 2023 Breast Cancer Update: Review of Breast Cancer Symposia
- 2023 Management of Checkpoint Inhibitor-Related Toxicity
- 2022 Management of Checkpoint Inhibitor-Related Toxicities
- 2022 Breast Cancer Update: Review of Breast Cancer Symposium
- 2021 Management of Checkpoint Inhibitor-Related Toxicity
- Breast Cancer Update: Review of Breast Cancer Symposia
- 7th Annual Multidisciplinary Colorectal Oncology Course
- ASCO 2020 Highlights
- 20th Annual ASH Review
- 2020 Management of Checkpoint Inhibitor-Related Toxicity
- 2020 Multidisciplinary Head and Neck Cancer Update
- 6th Annual Multidisciplinary Colorectal Oncology Course
- 5th Annual Cleveland Breast Cancer Summit
- 5th Annual Multidisciplinary Colorectal Oncology Course
- Breast
- GI
- GU
- Skin
- Lymphoma
- Leukemia
- Lung
- Gyn
- MDS/MPN
- Benign Hematology
- Myeloma
- Hematologic Malignancies
- Events
- Updates in Melanoma and High Risk Skin Cancer Management
Playback speed
10 seconds
Video Player is loading.
Current Time 0:00
/
Duration 6:45
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -6:45
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
- en (Main), selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
2019 ASH Review: The Use of Chromogenic Factor VIII Assay Changes Treatment Approach in a Portion of Mild Hemophilia a Patients With Factor VIII Assay Discrepancy
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Alice Ma
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Alice Ma
0 views
April 14, 2020
Comments 0
Login to view comments.
Click here to Login
Benign Hematology